Acquired haemophilia due to autoantibodies against factor VIII;Erworbene hämophilie infolge antikörperbildung gegen faktor VIII

Hamostaseologie

Volumn 23, Issue 1, 2003, Pages 28-35

  Von Depka Prondzinski, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acquired haemophilia; Autoimmune disease; Factor VIII inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; IDIOTYPIC ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ACQUIRED HEMOPHILIA; BLEEDING; BLEEDING TENDENCY; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; HEMOPHILIA A; HIGH RISK POPULATION; HUMAN; IMMUNOMODULATION; LYMPHOCYTE COUNT; MORBIDITY; MORTALITY; MUSCLE TISSUE; PATHOGENICITY; PROTHROMBIN TIME; REVIEW; SOFT TISSUE; SUBCUTANEOUS TISSUE;

EID: 18844468466     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619563     Document Type: Review

References (32)

1. Aledort LM. Immune tolerance induction: Is it cost effective? We know too little. Semin Thromb Hemost 2000; 26: 189-93.
2. Barthels M, Kraus M, Bohn U et al. Factor VIII inhibitor test could be less sensitive than supposed. Vox Sang 1999; 77 (Suppl 1): 87-9.
3. Brackmann HH, Gormsen J. Massive FVIII infusion in a haemophilic with FVIII inhibitor. High response. Lancet 1977; 2: 933.
4. Brackmann HH, Schwaab R, Effenberger W et al. Antibodies to FVIII in haemophilia A patients. Vox Sang 2000; 78: 187-90.
5. Colowick AB, Bohn RL, Avorn J et al. Immune tolerance induction in haemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-1702.
6. Ewenstein BM, Hoots WK, Lusher JM et al. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000; 85 (Suppl 10): 35-9.
7. Freiburghaus C, Berntorp E, Ekman M et al. Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995. Haemophilia 1998; 4: 16-29.
8. Green D, Lechner K. A survey of 215 nonhemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
9. Hay C, Negrier C, Ludlam C. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997; 78: 1463-7.
10. Jansen M, Schmaldienst S, Banyai S et al. Treatment of coagulation inhibitors with extracorporal immunoadsorption (Ig-TheraSorb). Br J Haematol 2001; 112: 91-7.
11. Julius U, Patzak A, Schaich M et al. Immunogene Thrombozytopenie, Anämie und Leukopenie während Schwangerschaft - Erfolgreiche Extrakorporaltherapie mit Immunadsorption. Dtsch Med Wochenschr 1997; 122: 220-4.
12. Kazatchkine MD, Lacroix-Desmazes S, Moreau A et al. Idiotypic regulation of anti-factor VIII antibodies. Haematologica 2000; 85 (Suppl 10): 97-9.
13. Knöbl P, Derfler K, Lorninger L et al. Elimination of acquired FVIII antibodies by extracorporeal antibody-based immunoadsorption/Ig-TheraSorb). Thromb Haemost 1995; 74: 1035-9.
14. Knöbl P, Derfler K. Extracorporeal immunoadsorption for the treatment of hemophilic patients with inhibitors to FVIII of XI. Vox Sang 1999; 77 (Suppl 1): 57-64.
15. Lottenberg R, Kentro T, Kitchen C. Acquired haemophilia: a natural history study of 16 patients with inhibitors to factor VIII. Thromb Haemost 1996; 76: 344-6.
16. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G et al. Low-dose immune tolerance induction in haemophilia A patients with inhibitors, Blood 1995; 86: 983-8.
17. Negrier C, Goudemand J, Sultan J et al. Multicenter retrospective study on the utilisation of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 11: 1113-9.
18. Nielssen IM, Jonsson S, Sundqvist SB et al. A procedure for removing high titer antibodies by extracorporal protein A sepharose adsorption in haemophilia: substitution therapy and surgery in patients with haemophilia B and antibodies. Blood 1981; 58: 38-44.
19. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in haemophilia A. Haematologica 2000; 85 (Suppl 10): 7-14.
20. Penner J. Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate Autoplex. Haemophilia 1999; 5 (Suppl. 3): 1-9.
21. Qian J, Burkly LC, Smith EP et al. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
22. Richter WO, Jacob BG, Ritter MM et al. Three-year treatment of familial hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal Apolipoprotein B antibodies. Metabolism 1993; 42: 888-94.
23. Scandella DH. Properties of anti-FVIII inhibitor antibodies in haemophilia A patients. Semin Thromb Hemost 2000; 26: 137-42.
24. Shapiro AD, Gilchrist GS, Hoots WK et al. Prospektive, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
25. Swoboda K, Derfler K, Koppensteiner R et al. Extracorporeal lipid elimination for treatment of gestational hyperlipidemic pancreatitis. Gastroenterology 1993; 104: 1527-31.
26. Toepfer M, Spannagl M, Sitter T et al. Successful reduction of acquired high titer FVIII antibodies by extracorporal antibody-based immunoadsorption. Nephrol Dial Transplant 1997; 12: A170.
27. Tribl B, Knöbl P, Derfler K et al. Rapid elimination of a high-titer spontaneous factor V antibody by extracorporal antibody-based immunoadsorption and immunosuppression. Ann Haematol 1995; 71: 199-203.
28. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with FVIII inhibitors. Haemophilia 2000; 6: 150-7.
29. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
30. Vermylen J. How do some haemophiliacs develop inhibitors? Haemophilia 1998; 4: 538-42.
31. Von Depka M, Huth-Kuehne A. Immunoadsorption with anti-immunoglobulin antibodies using Ig-TheraSorb columns. Lee C, Merchan-Rodriguez (eds), Blackwell Science 2002, 199-205.
32. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002; 100: 3426-8.